Abby Bova, MD
Hematology & Oncology · Oklahoma City, OKNPI 1013058452
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (44.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Novartis at 51.8% of the total.
Across 248 payments — averaging $24.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Pfizer$1K
- Merck$279
- Genentech USA, Inc.$207
- Array Biopharma Inc$189
- AbbVie$166
- plus $850 from 29 others
Across 8 payments — averaging $3787.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$20K
- Pfizer$10K
What the payments were for
- Food & beverage$2,66544%
- Education$71512%
- Other$2,66544%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 61 | $3,133 |
| Pfizer | 87 | $1,221 |
| Merck | 15 | $279 |
| Genentech USA, Inc. | 13 | $207 |
| Array Biopharma Inc | 11 | $189 |
| AbbVie | 10 | $166 |
| Astellas Pharma US Inc | 5 | $81 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Johnson & Johnson | 4 | $63 |
| Ipsen Biopharmaceuticals, Inc | 3 | $49 |
| Sanofi | 2 | $41 |
| Gilead(2 entities) | 3 | $40 |
| Eisai Inc. | 2 | $37 |
| Incyte Corporation | 2 | $35 |
| Seagen Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Recordati_rare_diseases_inc. | 2 | $32 |
| G1 Therapeutics, Inc. | 2 | $30 |
| AstraZeneca | 2 | $30 |
| Amgen | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Myovant Sciences Inc. | 1 | $21 |
| ADC Therapeutics America, Inc. | 1 | $19 |
| EMD Serono, Inc. | 1 | $15 |
| Bayer | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Verastem, Inc. | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $14 |
| Beigene USA, Inc. | 1 | $14 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $10 |
How this compares
$6,045 in reported general payments places this provider in the 70th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 72 | $1,083,783 |
| TagrissoOsimertinib Mesylate | 23 | $377,108 |
| CalquenceAcalabrutinib Maleate | 23 | $337,256 |
| LenvimaLenvatinib Mesylate | 13 | $316,901 |
| RubracaRucaparib Camsylate | 12 | $209,491 |
| KisqaliRibociclib Succinate | 12 | $163,455 |
| Lenalidomide | 12 | $147,602 |
| EliquisApixaban | 40 | $30,160 |
| XareltoRivaroxaban | 31 | $26,740 |
| Anastrozole | 605 | $18,609 |
| Exemestane | 109 | $12,745 |
| Everolimus | 13 | $7,090 |
| Letrozole | 162 | $5,042 |
| Enoxaparin Sodium | 13 | $2,533 |
| Imatinib Mesylate | 12 | $2,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $1,221 | $1,113,943112 claims |
| AstraZenecaTagrisso, Calquence | $30 | $714,36446 claims |
| Eisai Inc.Lenvima | $37 | $316,90113 claims |
| Clovis Oncology, Inc.Rubraca | $10 | $209,49112 claims |
| NovartisKisqali | $3,133 | $163,45512 claims |
| Johnson & JohnsonXarelto | $63 | $26,74031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Oklahoma City
- Romeo MandanasOklahoma City$160K
- Mohammad RazaqOklahoma City$56K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
- Hassan HatoumOklahoma City$23K
- Abdul Rafeh NaqashOklahoma City$23K
- Taha Al-JuhaishiOklahoma City$23K
- Adanma Anji Ayanambakkam AttanathiOklahoma City$16K
- Robert ReynoldsOklahoma City$15K
- Sadia ChohanOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.